Search

Author/Creator Mattison, Ryan J.

1. A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B‐cell non‐Hodgkin lymphoma: A Wisconsin Oncology Network study. Issue 19 (16th June 2015)

Authors:
Fenske, Timothy S.; Shah, Namrata M.; Kim, Kyung Mann; Saha, Sandeep; Zhang, Chong; Baim, Arielle E.; Farnen, John P.; Onitilo, Adedayo A.; Blank, Jules H.; Ahuja, Harish; Wassenaar, Tim; Qamar, Rubina; Mansky, Patrick; Traynor, Anne M.; Mattison, Ryan J.; Kahl, Brad S.
Journal:
Cancer
Issue:
Volume 121:Issue 19(2015)
Page Start:
3465
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. Issue 1 (2nd January 2021)

Authors:
Mushtaq, Muhammad Umair; Harrington, Alexandra M.; Chaudhary, Sibgha Gull; Michaelis, Laura C.; Carlson, Karen-Sue B.; Abedin, Sameem; Runass, Lyndsey; Callander, Natalie S.; Fallon, Michael J.; Juckett, Mark; Hall, Aric C.; Hematti, Peiman; Mattison, Ryan J.; Atallah, Ehab L.; Guru Murthy, Guru ...
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 1(2021)
Page Start:
158
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Issue 9 (20th March 2021)

Authors:
List, Alan F.; Sun, Zhuoxin; Verma, Amit; Bennett, John M.; Komrokji, Rami S.; McGraw, Kathy; Maciejewski, Jaroslaw; Altman, Jessica K.; Cheema, Puneet S.; Claxton, David F.; Luger, Selina M.; Mattison, Ryan J.; Wassenaar, Timothy R.; Artz, Andrew S.; Schiffer, Charles A.; Litzow, Mark R.; Tallma...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 9(2021)
Page Start:
1001
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Issue 7 (1st December 2020)

Authors:
Badar, Talha; Szabo, Aniko; Dinner, Shira; Liedtke, Michaela; Burkart, Madelyn; Shallis, Rory M.; Yurkiewicz, Ilana R.; Kuo, Eric; Khan, Muhammad Ali; Balasubramanian, Suresh; Yang, Jay; Hefazi, Mehrdad; Podoltsev, Nikolai; Patel, Anand; Curran, Emily; Wang, Amy; Arslan, Shukaib; Aldoss, Ibrahim;...
Journal:
Cancer
Issue:
Volume 127:Issue 7(2021)
Page Start:
1039
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗